Introduction: Prostate cancer is a major public health burden challenging the economic and health-care systems of many countries globally. It is the second-most frequently diagnosed malignancy after lung cancer and the fifth-leading cause of cancer-related deaths in men worldwide (1.7 million cases and 500 000 annual deaths expected by 2030. Most men have a diagnosis of localized prostate cancer and up to 99% 10-year survival, whereas the 5-year survival for individuals with late-stage disease is approximately 30%. Objectives: Analyze prostate cancer cases in the city of Belém do Pará and identify the main risk factors associated with the development of the disease.Methods: Descriptive study with a quantitative approach. To investigate the data, we used the variables contained in the SUS Hospital Information System (HIS), from 2016 to 2023. Results: Mortality data collected from Datasus between 2016 and 2023 shows that the city of Belém, Pará, has experienced a progressive increase in the number of deaths over the years. Over this 8-year period, a total of 217 deaths were recorded in the state capital. Notably, in 2021 alone, 40 deaths occurred, accounting for approximately 18.4% of all deaths in the period, a particularly alarming figure. Although the disease may be underreported, the data clearly shows the need for urgent public health actions to address and reverse this trend in Belém.Conclusion: As with other cancers, age is an important risk marker, and it takes on special significance in prostate cancer, since both incidence and mortality increase exponentially after the age of 50. The justifications that guide early detection of prostate cancer, as with any other topography, is that the earlier the disease is diagnosed, the greater the chances of cure, in addition to allowing for less aggressive and mutilating treatment. Early detection of prostate cancer could reduce the high costs resulting from the treatment of cancer in advanced stages or metastatic disease. The data analyzed are essential for us to focus primarily on the early detection of this neoplasm, which can be fatal to the life of any man. Any type of action that may be highlighted in the treatment and prevention of this neoplasm is of immediate importance.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
